Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.74 |
| ▸ | TP53 | P04637 | 2/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.74 |
| ▸ | CETP | P11597 | 6/20 | 0.67 |
| ▸ | MEN1 | O00255 | 4/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | THRB | P10828 | 3/20 | 0.67 |
| ▸ | ASAH1 | Q13510 | 2/20 | 0.65 |
| ▸ | ASAH2 | Q9NR71 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | GMNN | O75496 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | GLA | P06280 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | CXCR5 | P32302 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL315529 | 1.00 | MAPT (0.74) | MAPTCYP2D6MAPK1TP53CYP1A2 | |
| SCHEMBL6419171 | 1.00 | MAPT (0.74) | MAPTCYP2D6MAPK1TP53CYP1A2 | |
| SCHEMBL6410388 | 1.00 | MAPT (0.74) | MAPTCYP2D6MAPK1TP53CYP1A2 | |
| SCHEMBL10025150 | 1.00 | MAPT (0.74) | MAPTCYP2D6MAPK1TP53CYP1A2 | |
| SCHEMBL6410392 | 1.00 | MAPT (0.74) | MAPTCYP2D6MAPK1TP53CYP1A2 | |
| SCHEMBL16216319 | 0.95 | MAPT (0.65) | MAPTCYP2D6MAPK1TP53CYP1A2 | |
| SCHEMBL18069580 | 0.91 | MAPT (0.69) | MAPTCYP2D6MAPK1TP53CYP1A2 | |
| SCHEMBL15385494 | 0.89 | TP53 (0.57) | MAPTCYP2D6MAPK1TP53CYP1A2 | |
| SCHEMBL15385493 | 0.85 | TP53 (0.54) | MAPTCYP2D6MAPK1TP53CYP1A2 | |
| Acetyl Ceramide SCHEMBL58536 | 0.85 | MAPT (1.00) | MAPTCYP2D6MAPK1TP53CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024158254-A1 | METHOD FOR PRODUCING N-BOC-SPHINGOSINE AND SPHINGOSINE-1-PHOSPHATE | (주)유케이케미팜 | 2024-08-02 | — | — | WO | claimed |
| WO-2024158254-A1 | METHOD FOR PRODUCING N-BOC-SPHINGOSINE AND SPHINGOSINE-1-PHOSPHATE | (주)유케이케미팜 | 2024-08-02 | — | — | WO | disclosed |
| WO-2024158254-A1 | METHOD FOR PRODUCING N-BOC-SPHINGOSINE AND SPHINGOSINE-1-PHOSPHATE | (주)유케이케미팜 | 2024-08-02 | — | — | WO | disclosed |
| WO-2024158254-A1 | METHOD FOR PRODUCING N-BOC-SPHINGOSINE AND SPHINGOSINE-1-PHOSPHATE | (주)유케이케미팜 | 2024-08-02 | — | — | WO | disclosed |
| US-11857560-B2 | Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections | EMORY UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| WO-2023193341-A1 | SPHINGOLIPID COMPOUND, LIPOSOME CONTAINING SPHINGOLIPID COMPOUND, AND APPLICATION | 澳门科技大学 | 2023-10-12 | — | — | WO | disclosed |
| EP-4040965-A2 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | Emory University (US) | 2022-08-17 | — | — | EP | disclosed |
| CN-114867351-A | 4' -halo-containing nucleotide and nucleoside therapeutic compositions and uses related thereto | 埃默里大学 | 2022-08-05 | — | — | CN | disclosed |
| WO-2017189978-A1 | ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2017-11-02 | — | — | WO | disclosed |
| WO-2017155923-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017106710-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2017-06-22 | — | — | WO | disclosed |
| WO-2017106710-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2017-06-22 | — | — | WO | disclosed |
| US-20160220595-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2016-08-04 | — | — | US | disclosed |
| US-20160220595-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2016-08-04 | — | — | US | disclosed |
| US-9359389-B2 | Caged ceramide-1-phosphate derivatives | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2016-06-07 | — | — | US | disclosed |
| US-9359389-B2 | Caged ceramide-1-phosphate derivatives | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2016-06-07 | — | — | US | disclosed |
| WO-2015038596-A1 | NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2015-03-19 | — | — | WO | disclosed |
| EP-2446035-B1 | NOVEL DRUGS FOR INHIBITION OF GENE EXPRESSION | SYLENTIS SAU (ES) | 2015-03-11 | — | — | EP | disclosed |
| WO-2014124430-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2014-08-14 | — | — | WO | disclosed |
| US-20120238018-A1 | Caged Ceramide-1-Phosphate Derivatives | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2012-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160220595-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | PNP, NTPCR, TYMP | MAPT 2857/4885CYP2D6 3638/4885MAPK1 3781/4885 |
| US-20120238018-A1 | Caged Ceramide-1-Phosphate Derivatives | CERT1, SGMS1, CERS2 | MAPT 2333/4885CYP2D6 4857/4885MAPK1 4094/4885 |
| US-11857560-B2 | Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections | SLC28A1, PNP, SLC28A2 | MAPT 2451/4885CYP2D6 1022/4885MAPK1 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.